The GLP Journal

Medications

Drug-by-drug profiles: semaglutide, tirzepatide, liraglutide, and the next generation.

• 

  Medications

  Foundayo (Orforglipron): The First GLP-1 Pill With No Food or Water Rules

  Lilly's oral GLP-1 was approved April 2026 and starts at $149 a month. What ATTAIN-1 actually showed, the drug interactions peptide GLP-1s don't have, and the unusual boxed warning.

  9 min read · Updated Oct 11, 2026

• 

  Medications

  Semaglutide: Dosing, Side Effects, and Real-World Data

  The molecule behind Wegovy and compounded semaglutide — mechanism, dosing, and what the trials show.

  10 min read · Updated Oct 28, 2026

• 

  Medications

  Tirzepatide: The Dual Receptor Agonist Explained

  How tirzepatide targets both GIP and GLP-1 receptors, and what the SURMOUNT trials found.

  10 min read · Updated Oct 10, 2026

• 

  Medications

  Liraglutide: The First-Generation GLP-1

  The original GLP-1 receptor agonist — daily dosing, the SCALE trials, and where it fits today.

  8 min read · Updated Sep 11, 2026

• 

  Medications

  Retatrutide: The Triple Agonist in Development

  The triple agonist targeting GLP-1, GIP, and glucagon — what the TRIUMPH Phase 3 trials showed.

  9 min read · Updated Sep 10, 2026